The Influence Of Different Myelosuppression Degrees During Chemotherapy On The Prognosis Of Triple-negative Breast Cancer

AimThis study analyzed the survival rate of mild and severe myelosuppression after adjuvant chemotherapy for triple-negative breast cancer,explored the relationship between myelosuppression and prognosis,and improved the prognosis of patients with triple-negative breast cancer.MethodA retrospective study of the clinical,pathological and follow-up data of 168 patients with TNBC in the Department of Breast Surgery,the Third Affiliated Hospital of Zhengzhou University from January 2012 to December 2017.The use of epirubicin and cyclophosphamide during adjuvant chemotherapy followed by docetal Competition(EC-T)program.The patients in the group were divided into group A(grade 0/I/II)and group B(grade III/IV)according to the degree of bone marrow suppression by WHO.Disease-free survival(DFS),local-regional recurrence-free survival(LRFS),distant recurrence-free survival(DRFS)and overall survival(OS)were used to assess the prognosis of patients in the group and analyze the clinicopathological characteristics between the two groups.Result1.Survival analysis of mild and severe myelosuppressionThe 5-year DFS rate of the severe group(78.3%)>the mild group(69.2%);the5-year OS rate of the severe group(91.1%)>the mild group(83.3%);the 5-year LRFS rate of the severe group(89.1%)> Mild group(83.3%);5-year DRFS rate of severe group(85.5%)> Mild group(77.0%),of which DFS and DRFS of both light and recombination groups were statistically significant(P<0.05),There was no significant difference in OS and LRFS between the light and recombination groups(P>0.05).2.Clinicopathological characteristics of mild and severe myelosuppressionThe baseline clinicopathological characteristics of the two groups of patients were not significantly different(all P<0.05).ConclusionThe prognosis of TNBC patients with Ⅲ-Ⅳ degree myelosuppression after EC-T regimen adjuvant chemotherapy is better than 0-Ⅱ degree;...